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1 |  INTRODUCTION
Epidemiological studies consistently indicate that alcohol 
is an independent risk factor for female breast cancer (BC) 
(Singletary & Gapstur, 2001). The International Agency 
for Research on Cancer concluded that there is sufficient 
evidence to classify alcohol as a carcinogen for female BC 
(IARC Working Group on the Evaluation of Carcinogenic 
Risks to Humans, 2010). One hypothesized mechanism be-
hind alcohol‐related breast carcinogenesis is the involvement 
of acetaldehyde, a metabolite of ethanol. An impact of ac-
etaldehyde on carcinogenesis for several types of alcohol‐
induced cancers has been shown in experimental models 
(Brooks & Theruvathu, 2005). Molecular epidemiological 
studies demonstrated a gene‐environment interaction be-
tween a functional aldehyde dehydrogenase 2 (ALDH2) poly-
morphism (rs671: Glu>Lys, OMIM: 100650) and alcohol 
intake for esophageal and upper digestive tract cancers in East 
Asian countries (Matsuo et al., 2001; Oze et al., 2010), where 
rs671 is prevalent (Li et al., 2009). These studies support 
the hypothesis that acetaldehyde is a carcinogen. The Glu/
Lys heterozygotes of rs671 have far less than half of ALDH2 
activity of Glu/Glu homozygotes, and the Lys/Lys homozy-
gotes have no detectable ALDH2 activity, which leads to high 
acetaldehyde concentrations upon alcohol intake in individu-
als harboring the Lys allele (Crabb, Edenberg, Bosron, & Li, 
1989). Therefore, exploring the association of rs671 with BC 
risk and its interaction with alcohol intake is one approach to 
elucidate whether acetaldehyde is a causative agent for breast 
carcinogenesis. To date, evidence of an association of rs671 
with BC risk is scarce; statistically significant associations 
have not been observed in case‐control studies in Japan (456 
cases and 912 controls) (Kawase et al., 2009) Korea (346 
cases and 377 controls) (Choi et al., 2003) or Thailand (561 
cases and 486 controls) (Sangrajrang et al., 2010). We con-
ducted a pooled analysis of individual genetic and alcohol 
consumption data for women of Asian ancestry participat-
ing in studies in the Breast Cancer Association Consortium 
(BCAC) with at least 18 times larger sample size than previ-
ous studies.
Abstract
Background: Epidemiological studies consistently indicate that alcohol consumption is an 
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2 (ALDH2) polymorphism (rs671: Glu>Lys) has a strong effect on acetaldehyde metabolism, 
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Asian ancestry women participating in the Breast Cancer Association Consortium.
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and BC risk, and 2,849 invasive BC cases and 3,680 controls for the analysis of the gene‐envi-
ronment interaction between rs671 and alcohol intake for BC risk. The pooled odds ratios (OR) 
with 95% confidence intervals (CI) associated with rs671 and its interaction with alcohol intake 
for BC risk were estimated using logistic regression models.
Results: The Lys/Lys genotype of rs671 was associated with increased BC risk (OR = 1.16, 
95% CI 1.03–1.30, p = 0.014). According to tumor characteristics, the Lys/Lys genotype was 
associated with estrogen receptor (ER)‐positive BC (OR = 1.19, 95% CI 1.05–1.36, p = 0.008), 
progesterone receptor (PR)‐positive BC (OR = 1.19, 95% CI 1.03–1.36, p = 0.015), and human 
epidermal growth factor receptor 2 (HER2)‐negative BC (OR  =  1.25, 95% CI 1.05–1.48, 
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tive tumor types.
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2 |  METHODS
2.1 | Study population
We used data from 14 case‐control studies in the BCAC. 
Table 1 shows participating studies contributing to this pooled 
analysis. All study participants were of Asian ancestry and 
recruited from studies conducted in Asian countries, Canada, 
and the USA. Eight studies were hospital‐based, five were 
population‐based, and one included hospital‐based cases and 
population‐based controls. We included 12,595 BC cases and 
12,884 controls for the analysis of rs671 and BC risk. For the 
analysis of the gene‐environment interaction between rs671 
and alcohol intake for BC risk, we included 2,849 BC cases 
and 3,680 controls after excluding participants with missing 
values for alcohol intake from seven studies. All studies were 
approved by their local ethics review boards, and all par-
ticipants provided informed consent. This investigation was 
approved by a human research investigations committee at 
Aichi Cancer Center.
2.2 | Genotyping methods
Genotyping was carried out using the iCOGS array (http://
ccge.medsc hl.cam.ac.uk/resea rch/conso rtia/icogs/ ), or the 
OncoArray (https ://suppo rt.illum ina.com/downl oads/infin 
ium-oncoa rray-500k-v1-0-produ ct-files.html). Details of 
array design, genotyping, postgenotyping quality control, 
and imputation have been provided elsewhere (Michailidou 
et al., 2013, 2017). The rs671 SNP on ALDH2 was a can-
didate SNP selected on the basis of specific hypotheses de-
scribed above.
To adjust for potential population stratification, princi-
pal components analyses (PCA) were carried out separately 
for Asian subgroups. Briefly, PCA was performed based on 
a subset of 37,000 uncorrelated SNPs for the iCOGS data 
and based on 33,661 uncorrelated SNPs for the OncoArray 
data. For the present analyses, we used two Asian principal 
components for the iCOGS dataset and 10 Asian principal 
components for the OncoArray dataset as covariates. Further 
details have been provided in previous articles (Michailidou 
et al., 2013, 2017).
2.3 | Alcohol assessment
Each study ascertained alcohol intake via self‐reported ques-
tionnaire. Daily alcohol intake in grams was determined by 
summing the product of frequency of consumption of speci-
fied alcoholic beverages (beer, wine, and other alcoholic 
beverages) by the alcohol content of each beverage using 
national estimates of alcohol content for that country. The 
exposure period was the year preceding recruitment. A mul-
tistep harmonization procedure was used to reconcile differ-
ences in individual study questionnaires.
2.4 | Statistical analysis
To assess the associations of rs671 with BC risk, we esti-
mated odds ratios (ORs) with 95% confidence intervals (CIs) 
by unconditional logistic regression models using the Glu/
Glu genotype as reference. This was done separately for 
iCOGS and OncoArray datasets, and results were combined 
by a fixed‐effects meta‐analysis. The ORs were adjusted for 
age, Asian principal components, and study. We also evalu-
ated the associations by tumor characteristics (estrogen re-
ceptor, ER; progesterone receptor, PR; human epidermal 
growth factor receptor 2, HER2) and tumor subtypes (lumi-
nal [either ER or PR positive, HER2 negative], triple positive 
[ER, PR, HER2 positive], HER2 enrich [ER, PR negative, 
HER2 positive], triple negative [ER, PR, HER2 negative]) 
using cases with these specific characteristics. Heterogeneity 
by tumor characteristics and between studies was assessed 
using Cochran's Q test. We assessed the gene‐environment 
interaction between rs671 and alcohol intake by including 
an interaction term. Alcohol intake was classified in three 
ways: 1) two categories (none, any alcohol intake); 2) three 
categories (none, <15  g ethanol/day, ≥15  g ethanol/day); 
and 3) four categories (none, <15  g ethanol/day, 15–30  g 
ethanol/day, ≥30 g ethanol/day). We also performed strati-
fied analyses by menopausal status: women with missing 
menopausal status were considered premenopausal if they 
were ≤50 years or postmenopausal if >50 years. All statisti-
cal analyses were performed using Stata version 15.1 (Stata 
Corp., College Station, TX, USA), with a P value <0.05 con-
sidered to be statistically significant.
3 |  RESULTS
Demographic characteristics of participants are shown in 
Table 2. The median age was 50 years for both cases and 
controls, with a higher proportion of women in the oldest age 
groups for cases. The proportion of nondrinkers and heavy 
drinkers (≥15  g ethanol/day) was higher among controls 
than cases, possibly due to the smaller number of unknown 
category in controls (71.4%) than in cases (77.4%). The dis-
tributions of tumor characteristics among cases were 7,648 
ER positive (60.7%), 6,308 PR positive (50.1%), and 3,054 
HER2 positive (24.3%) for participants included in the anal-
ysis of rs671 alone and, 1,871 ER positive (65.7%), 1,620 PR 
positive (56.9%), and 552 HER2 positive (19.4%) for those 
in the analysis of gene‐environment interaction, respectively.
Table 3 presents the associations of rs671 with BC risk. 
Overall, the Lys/Lys genotype was associated with increased 
BC risk, with OR of 1.16 (95% CI = 1.03–1.30, p = 0.014) 
relative to Glu/Glu genotype. According to tumor characteris-
tics, we observed an association of the Lys/Lys genotype with 
ER‐positive BC (OR = 1.19, 95% CI 1.05–1.36, p = 0.008), 
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PR‐positive BC (OR = 1.19, 95% CI 1.03–1.36, p = 0.015), 
and HER2‐negative BC (OR  =  1.25, 95% CI 1.05–1.48, 
p = 0.012), but not with ER‐negative BC (OR = 1.07, 95% 
CI 0.90–1.27, p = 0.453), PR‐negative BC (OR = 1.13, 95% 
CI 0.95–1.34, p = 0.176), or HER2‐positive BC (OR = 1.19, 
95% CI 0.97–1.48, p = 0.102), although no statistically sig-
nificant heterogeneity was observed by tumor characteristics. 
According to tumor subtypes, the Lys/Lys genotype was only 
associated with luminal BC (OR = 1.30, 95% CI 1.09–1.55, 
p = 0.004), and not with other subtypes (Table 4). No evidence 
of heterogeneity was also observed by menopausal status 
(Table S1).
Figure S1 and Figure S2 show the forest plots of study‐
specific ORs for the association between rs671 and BC risk. 
With regard to the association between the Glu/Lys genotype 
and BC risk, there was no evidence of between‐study hetero-
geneity (p for heterogeneity = 0.380). In contrast, significant 
between‐study heterogeneity was observed for the associ-
ation of the Lys/Lys genotype with BC risk (p for hetero-
geneity = 0.003), which was mainly attributable to a strong 
positive association for CBCS and a strong inverse association 
for ACP and TWBCS. However, exclusion of these studies 
did not alter the significant association of the Lys/Lys geno-
type with BC risk (OR = 1.18, 95% CI 1.05–1.33, p = 0.008) 
T A B L E  3  Association between ALDH2 genotype and breast cancer risk
 
ALDH2 genotype
p for heterogeneity between tumor 
characteristics
Glu/Glu Glu/Lys Lys/Lys For Glu/Lys For Lys/Lys
Overall
Cases/controls 7,781/8,038 4,070/4,175 744/671    
OR (95% CI)† 1 (ref.) 1.03 (0.97–1.08, 
p = 0.350)
1.16 (1.03–1.30, 
p = 0.014)
   
ER status
Positive          
Cases/controls 4,636/8,038 2,531/4,175 481/671    
OR (95% CI)† 1 (ref.) 1.01 (0.95–1.08, 
p = 0.669)
1.19 (1.05–1.36, 
p = 0.008)
0.447 0.329
Negative
Cases/control 2,321/8,038 1,187/4,175 193/671    
OR (95% CI)† 1 (ref.) 1.05 (0.97–1.14, 
p = 0.257)
1.07 (0.90–1.27, 
p = 0.453)
   
PR status
Positive
Cases/controls 3,842/8,038 2,066/4,175 400/671    
OR (95% CI)† 1 (ref.) 0.98 (0.92–1.05, 
p = 0.591)
1.19 (1.03–1.36, 
p = 0.015)
0.410 0.653
Negative
Cases/control 2,333/8,038 1,238/4,175 205/671    
OR (95% CI)† 1 (ref.) 1.02 (0.95–1.11, 
p = 0.545)
1.13 (0.95–1.34, 
p = 0.176)
   
HER2 status
Positive
Cases/control 1,961/8,038 940/4,175 153/671    
OR (95% CI)† 1 (ref.) 1.02 (0.92–1.14, 
p = 0.674)
1.19 (0.97–1.48, 
p = 0.102)
1.000 0.720
Negative
Cases/control 2,521/7,841 1,287/4,175 246/671    
OR (95% CI)† 1 (ref.) 1.02 (0.93–1.11, 
p = 0.722)
1.25 (1.05–1.48, 
p = 0.012)
   
Abbreviations: ALDH2, aldehyde dehydrogenase 2; CI, confidence intervals; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; OR, odds 
ratios; PR, progesterone receptor.
†ORs were adjusted for age (continuous), Asian principal components and study site. 
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and there was no longer evidence of between‐study heteroge-
neity (p for heterogeneity = 0.133). Furthermore, when we 
repeated analyses using random effects meta‐analyses to cal-
culate summary study‐specific estimates, the results did not 
change substantially (Table S2).
Stratified analyses by alcohol intake categories assessing 
a gene‐environment interaction between rs671 and alcohol 
intake showed no evidence of interaction, although the sam-
ple size is small compared to the analysis of rs671 and BC 
risk (Table S3, p for interaction = 0.537).
4 |  DISCUSSION
In this study, we found that the Lys/Lys genotype of rs671 
was associated with increased BC risk among women of 
Asian ancestry. No evidence of interaction was observed 
between rs671 and alcohol intake. This is the largest study 
to date to perform this evaluation quantitatively using high‐
quality individual‐level data for Asian women.
Several epidemiological studies have reported a gene‐en-
vironment interaction between rs671 and alcohol intake for 
several types of cancer (Hiraki et al., 2007; Ishioka et al., 
2018; Masaoka et al., 2016; Matsuo et al., 2001, 2013; Oze et 
al., 2010). Our findings are not consistent with our hypothesis 
of gene‐environment interaction between rs671 and alcohol 
intake. Considering the established impact of rs671 on cancer 
risk, this lack of interaction suggests that acetaldehyde may 
be less influential in breast carcinogenesis. Other biological 
mechanisms for alcohol‐related breast carcinogenesis have 
been hypothesized, including increased circulating estrogens 
and androgens, enhancement of mammary gland susceptibil-
ity to carcinogenesis, increased mammary carcinogen DNA 
damage, interference of folate metabolism by alcohol, and 
greater potential for invasiveness into BC cells (Bernstein 
& Ross, 1993; Singletary & Gapstur, 2001; Singletary & 
McNary, 1994; Stolzenberg‐Solomon et al., 2006). To bet-
ter understand the etiologic nature of the effect of alcohol on 
breast carcinogenesis, further investigations are needed.
We observed an association of the Lys/Lys genotype 
with increased BC risk. Because individuals with the Lys/
Lys genotype have no detectable ALDH2 activity and 
almost completely refrain from drinking due to severe 
adverse reactions caused by acetaldehyde (e.g., facial 
flushing, nausea and headache) (Matsuo et al., 2006), the 
observed genetic association suggests that the Lys/Lys 
genotype confers susceptibility to BC risk independently 
of alcohol intake. ALDH2 plays a key role in removal 
of not only ethanol‐derived  acetaldehyde, but also other 
toxic endogenous aldehydes such as 4‐hydroxy‐2‐nonenal 
(4‐HNE) and malondialdehyde (Chen, Ferreira, Gross, & 
Mochly‐Rosen, 2014). These endogenous aldehydes have 
been reported to cause DNA damage and might be related 
to breast carcinogenesis (Chen et al., 2014; Garaycoechea 
et al., 2018). In addition, we did not find an association 
of the Glu/Lys genotype with BC risk. This suggest that 
T A B L E  4  Association between ALDH2 genotype and breast cancer risk by tumor subtypes
 
ALDH2 genotype
p for heterogeneity between tumor 
characteristics
Glu/Glu Glu/Lys Lys/Lys For Glu/Lys For Lys/Lys
Luminal
Cases/controls 1,950/8,038 979/4,175 198/671    
OR (95% CI)† 1 (ref.) 1.00 (0.92–1.10, 
p = 0.916)
1.30 (1.09–1.55, 
p = 0.004)
0.452 0.755
Triple positive
Cases/controls 1,202/8,038 583/4,175 93/671    
OR (95% CI)† 1 (ref.) 1.03 (0.91–1.16, 
p = 0.640)
1.19 (0.93–1.53, 
p = 0.164)
   
HER2 enrich
Cases/controls 694/8,038 322/4,175 55/671    
OR (95% CI)† 1 (ref.) 0.96 (0.83–1.11, 
p = 0.557)
1.12 (0.83–1.51, 
p = 0.453)
   
Triple negative
Cases/control 546/8,038 310/4,175 46/671    
OR (95% CI)† 1 (ref.) 1.13 (0.97–1.32, 
p = 0.108)
1.11 (0.81–1.53, 
p = 0.519)
   
Abbreviations: ALDH2, aldehyde dehydrogenase 2; CI, confidence intervals; HER2, human epidermal growth factor receptor 2; OR, odds ratios.
†ORs were adjusted for age (continuous), Asian principal components and study site. 
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ALDH2 activity of the Glu/Lys homozygotes may be suf-
ficient for detoxifying toxic endogenous aldehydes related 
to breast carcinogenesis. In contrast, the Lys/Lys homozy-
gotes have no detectable ALDH2 activity, thus may not tol-
erate these endogenous aldehydes. Furthermore, the Lys/
Lys genotype was associated with increased risk only in 
hormone receptor positive BC, and not in hormone recep-
tor negative BC. These results suggest that the biological 
mechanism could be through a hormonal receptor medi-
ated pathway (Zhang, Man, Zhao, Dong, & Ma, 2014). The 
evidence of an association of rs671 with BC risk is scarce 
and may warrant additional evaluation in future studies.
The strengths of this investigation include the analysis of 
individual‐level data from a large sample of Asian women, al-
lowing us to obtain stable, and precise summary estimates of 
the association of rs671 with BC risk. Other strengths are the 
uniform genotyping procedures and quality‐control measures 
undertaken for the iCOGS and the OncoArray, respectively. 
We were also able to control for population stratification by 
including Asian principal components as a covariate to con-
trol for residual genetic heterogeneity. Furthermore, the Lys 
allele of rs671 is only prevalent in East Asia, and has not been 
found in Caucasians or Africans (Li et al., 2009). Thus, this 
analysis is unique and can be performed only among Asian 
women. Several limitations also warrant consideration. First, 
we could not evaluate the association between alcohol intake 
and BC risk because there were a lot of missing data on po-
tential confounding factors (e.g., smoking, estrogen‐related 
factors) and we were not able to control for them. However, 
genotypes are fixed at birth and these factors cannot influence 
genotypes; therefore, our results about rs671 and BC risk may 
be unbiased even though we did not adjust for these factors. 
Second, even though all study participants were of Asian an-
cestry, the heterogeneity across study populations, designs, 
and methods are potential limitations. Third, careful interpre-
tation of results from the analysis of gene‐environment inter-
action and stratified analyses is necessary because we had a 
limited number of participants in some sub‐groups and did 
not adjust for multiple comparisons.
In conclusion, we observed an association between the 
Lys/Lys genotype of rs671 and increased BC risk. Among 
women of Asian ancestry, this study suggests that the Lys/
Lys genotype confers susceptibility to BC risk, particularly for 
ER‐positive, PR‐positive, and HER2‐negative tumor types. 
These findings warrant further investigation in future studies.
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